Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene modifiers in pediatric asthma management.

H Bisgaard1

  • 1Department of Paediatrics, Copenhagen University Hospital, Copenhagen, Denmark. bisgaard@copsac.dk

Pediatrics
|February 7, 2001
PubMed
Summary

Cysteinyl leukotrienes (Cys-LTs) are key mediators in asthma. Leukotriene modifiers offer a safe and effective treatment option, particularly for children, complementing other asthma therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ecological succession in the vaginal microbiota during pregnancy and birth.

The ISME journal·2020
Same author

17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use.

Allergy·2018
Same author

Neonates colonized with pathogenic bacteria in the airways have a low-grade systemic inflammation.

Allergy·2018
Same author

Allergic sensitization at school age is a systemic low-grade inflammatory disorder.

Allergy·2016
Same author

Domestic dog exposure at birth reduces the incidence of atopic dermatitis.

Allergy·2016
Same author

High breast milk IL-1β level is associated with reduced risk of childhood eczema.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Cysteinyl leukotrienes (Cys-LTs) are potent mediators implicated in asthma pathophysiology.
  • Corticosteroids show limited efficacy in inhibiting Cys-LT release in vivo.
  • Cys-LTs contribute to bronchoconstriction, inflammation, and airway remodeling in chronic asthma.

Purpose of the Study:

  • To evaluate the role of Cys-LTs in asthma.
  • To assess the efficacy and safety of leukotriene modifiers (LT modifiers) in asthma management.
  • To explore the utility of Cys-LT receptor antagonists (Cys-LTRA) in pediatric asthma.

Main Methods:

  • Review of blocking studies demonstrating the pivotal role of Cys-LTs.
  • Analysis of Phase III randomized controlled trials (RCTs) on LT modifiers.
  • Examination of clinical trial data for Cys-LTRA, including montelukast, in pediatric populations.

Main Results:

  • LT modifiers reduce airway eosinophils and exhaled nitric oxide.
  • Cys-LTRA are well-tolerated with moderate efficacy, showing additive effects with beta-agonists and corticosteroids.
  • Montelukast demonstrates efficacy and bronchoprotection in preschool children with asthma.

Conclusions:

  • Cys-LTs play a significant role in asthma airway inflammation.
  • LT modifiers are valuable alternatives for pediatric asthma management, offering bronchodilation and bronchoprotection.
  • LT modifiers are effective, safe, and orally administered options for treating asthmatic children.

Related Experiment Videos